Clinical trials: Histological Response
Hepatocellular Carcinoma
Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma
The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients.
- Trial name
- NCT02550613
- Testing
- The imaging biomarkers determined by MR-PET
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Sarcoma, Kaposi, HIV Infections
A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma
To evaluate the safety and toxicity of combination therapy for AIDS-associated Kaposi's sarcoma with zidovudine (AZT) and two kinds of interferon alpha.
- Trial name
- NCT00000725
- Testing
- Interferon alfa-2a, Zidovudine, Interferon alfa-n1
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Carcinoma, Small Cell
Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY)
Main objective: To evaluate whether the subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting on the first day of chemotherapy (CT), delays tumoral spread and increases progression-free survival.
- Trial name
- NCT00324558
- Testing
- Bemiparin
- Where
- 15 sites in Spain
- Volunteers
- 39 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Carcinoma, Hepatocellular
SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE
This is a pilot study where patients with Hepatocellular Carcinoma (HCC) that have failed Transarterial Chemoembolization (TACE) will be treated with Stereotactic Body Radiation Therapy (SBRT).
- Trial name
- NCT02221778
- Testing
- SBRT
- Where
- Brazil
- Volunteers
- 25 people
- Sponsor
- University of Sao Paulo
Oral Cavity Squamous Cell Carcinoma
Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction
Safety and tolerability of neoadjuvant nivolumab for locally advanced resectable oral cancer, combined with [18F]BMS-986192 / [18F]-FDG PET imaging and immunomonitoring for response prediction
- Trial name
- NeoNivo (NCT03843515)
- Testing
- Nivolumab
- Where
- Netherlands
- Volunteers
- 17 people
- Sponsor
- Amsterdam UMC, location VUmc
Chronic Myelogenous Leukemia - Chronic Phase
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance.
- Trial name
- ASC2ESCALATE (NCT05384587)
- Testing
- asciminib
- Where
- 80 sites in United States
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
HEAD AND NECK CANCER, CARCINOMA OROPHARYNX
Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer.
This study aims to study the impact image guided radiotherapy with Cone beam CT will have on the outcomes(toxicities and response) of head and neck cancer when compared to 3D conformal radiotherapy without CBCT based setup error…
- Conditions
- HEAD AND NECK CANCER, CARCINOMA OROPHARYNX, CARCINOMA PYRIFORM SINUS, CARCINOMA LARYNX
- Trial name
- NCT01124409
- Testing
- EPID Verification, CBCT verification
- Where
- India
- Volunteers
- 41 people
- Sponsor
- All India Institute of Medical Sciences
Ovarian Cancer
Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
This is an open-label, single-arm, international, multicenter Multiple Patient Expanded Access Program (MPEAP). The program is designed to provide treatment access to olaparib tablets for patients with platinum-sensitive relapsed…
- Trial name
- NCT03079687
- Testing
- Olaparib tablets
- Where
- 13 sites in United States
- Sponsor
- AstraZeneca
Advanced Solid Tumors
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.
The therapeutic approach taken by trial SAKK 66/17 is different from those already used in clinical practice and possibly offers patients a therapeutic benefit after failure of standard chemotherapy and immunotherapy.
- Trial name
- NCT03993678
- Testing
- IP-001, Thermal Ablation
- Where
- 3 sites in Switzerland
- Volunteers
- 28 people
- Sponsor
- Swiss Cancer Institute
Neuroendocrine Tumors
Octreotide LAR in the Induction of Immunologic Response in NENs Patients
Evaluating the impact of OCTREOTIDE LAR on the immune response by studying Regulatory T-cell (T-Reg) and Myeloid-derived suppressor cells (MDSC) and the immunoregulatory cell population in peripheral blood of NET G1 / G2 patients…
- Trial name
- CSMS99 (NCT04129255)
- Testing
- Octreotide Acetate
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute, Naples
Nasal Polyps
Medical Polypectomy and Predictors of Response
This is the first randomized parallel group clinical trial looking at oral prednisolone induced medical nasal polypectomy followed by maintenance on topical steroid therapy in patients with nasal polyposis.
- Trial name
- NCT00788749
- Testing
- Prednisolone, fluticasone nasal drops, fluticasone nasal spray
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Dundee
Hepatocellular Carcinoma
Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer
This phase II trial studies how well perflutren protein-type A microspheres and contrast-enhanced ultrasound work in improving response to radioembolization therapy in patients with liver cancer.
- Trial name
- NCT03199274
- Testing
- Yttrium-90 Microsphere Radioembolization, Perflutren Protein-Type A Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Thomas Jefferson University
Cancer, Pancreatic Cancer
9-ING-41 in Patients With Advanced Cancers
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in…
- Conditions
- Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer
- Trial name
- NCT03678883
- Testing
- 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin.
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 350 people
- Sponsor
- Actuate Therapeutics Inc.
Chronic Myelogenous Leukemia in Chronic Phase
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
"This is a single-arm, open-label, multi-center study of complete molecular response (CMR) in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP).
- Trial name
- MACS1428 (NCT01227577)
- Testing
- Nilotinib
- Where
- 32 sites in United States
- Volunteers
- 128 people
- Sponsor
- Novartis Pharmaceuticals
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
This phase III clinical trial studies two different dose schedules of paclitaxel to see how well they work in combination with carboplatin with or without bevacizumab in treating patients with stage II, III or IV ovarian…
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Ovarian Brenner Tumor
- Trial name
- NCT01167712
- Testing
- Bevacizumab, Carboplatin, Computed Tomography
- Where
- 564 sites in United States, Canada and 1 more
- Volunteers
- 692 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Other, Cancer
A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec
1.0 OBJECTIVES 1.1 To test the activity of arsenic trioxide in combination with imatinib in patients with CML with cytogenetic evidence of residual disease. 1.2 To determine the toxicity associated with this therapy.
- Trial name
- NCT00250042
- Testing
- Gleevec and Arsenic Trioxide
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- New Mexico Cancer Research Alliance
Adenocarcinoma Esophagus
Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE) Junction Adenocarcinoma
This is an observational study to determine the feasibility of assessing tumor response utilizing ctDNA in patients of locally advanced esophageal and gastroesophageal junction (LA-EA/GEJ) cancer undergoing total neoadjuvant…
- Trial name
- TRACT DNA (NCT05067842)
- Testing
- Circulating tumor DNA(ctDNA) level measurement
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Melanoma
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
To assess the response of melanoma with brain metastases to ipilimumab treatment while maintaining acceptable tolerability.
- Trial name
- NCT00623766
- Testing
- Ipilimumab, Corticosteroid: Betamethasone, Corticosteroid: Dexamethasone
- Where
- 14 sites in United States
- Volunteers
- 99 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Renal Cell Carcinoma
A Retrospective Real World Analysis Of Sutent In Patients With Metastatic Renal Cell Carcinoma In Community And Academic Centers To Assess The Impact Of Dose Variation On Duration Of Response And Overall Survival
This is a retrospective, non-interventional study which looks at the cohort of Renal Cell Carcinoma patients in a real life clinical setting and analyses into factors why these patients have been surviving for as long as 3-5…
- Trial name
- NCT01917214
- Testing
- Sutent: Observational Study
- Volunteers
- 212 people
- Sponsor
- Pfizer
Chronic Myeloid Leukemia
A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region
The aim of this study is to evaluate the real-world effectiveness and safety of asciminib among young adults with chronic myeloid leukemia (CML) across the Gulf region.
- Trial name
- ASC4Young (NCT07681258)
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.